US-based Odyssey Thera has received a US patent for protein-fragment complementation assays process in whole animals.
Subscribe to our email newsletter
The patent describes a method for detecting protein-protein interactions in living cells and animals. Protein interactions define the intricate biochemical networks in living cells, and are used at Odyssey Thera to monitor drug response. The invention is said to help monitor specific biochemical parameters, including the extent and kinetics of drug target modulation, in a live subject.
John Westwick, CEO of Odyssey Thera and co-author on the patent, said: “This patent extends our broad estate in drug discovery technologies. With this invention, drug discovery and development are achieved with a single system that faithfully monitors the activity of a drug at each step.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.